
    
      PF-3512676 dosing was stopped 20 June 2007 in response to DSMC recommendation to close the
      trial, citing lack of efficacy concerns as the primary reason with a safety issue (sepsis)
      also contributing to the decision. Subjects were allowed to complete standard of care
      treatment/survival follow-up. Data collection was completed on 17 July 2008.
    
  